Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 27, 2016
Principal Office: Malvern, PA
This filing discloses a contemplated private placement of common stock and the delivery of an investor presentation. The document serves as a Regulation FD disclosure and does not constitute an offer to sell securities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a proposed capital raise.
- Proposed Private Placement: 1,081,082 shares of common stock.
- Purchase Price: $18.50 per share.
- Estimated Gross Proceeds: Approximately $20 million (calculated from share count and price).
Material Changes
No material changes to historical financial performance or operations are reported in this document. The primary event is the announcement of the contemplated private placement to raise capital.
Guidance, Outlook, and Risks
Management Commentary: The Company presented an investor presentation (Exhibit 99.2) in connection with the private placement. The filing explicitly states that the information speaks only as of the date of the report.
Disclaimers and Risks:
- The Company disclaims any obligation to update the information contained in this report in the future, except as required by applicable law.
- Neither the report nor its exhibits are an offer to sell or a solicitation of an offer to buy securities.
- The information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the final closing status of the private placement (1,081,082 shares at $18.50/share).
- Review the attached Investor Presentation (Exhibit 99.2) for updated business strategy and financial projections.
- Confirm the use of proceeds from the capital raise.
- Check subsequent filings for any updates or changes to the offering terms.